| Nome |
# |
|
COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors, file e177fbc7-a3c0-50b0-e053-d805fe0adaee
|
80
|
|
Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients, file e177fbc7-a312-50b0-e053-d805fe0adaee
|
72
|
|
The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients, file e177fbc7-1dff-50b0-e053-d805fe0adaee
|
50
|
|
Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study, file e177fbc7-a7a8-50b0-e053-d805fe0adaee
|
46
|
|
Accuracy of fine needle aspiration cytology in the pathological typing of non-small cell lung cancer., file e177fbc4-2cf3-50b0-e053-d805fe0adaee
|
45
|
|
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib, file e177fbc7-275c-50b0-e053-d805fe0adaee
|
42
|
|
Monitoring cfDNA in plasma and in other liquid biopsies of advanced EGFR mutated NSCLC patients: A pilot study and a review of the literature, file e177fbc7-aa2c-50b0-e053-d805fe0adaee
|
42
|
|
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial, file e177fbc7-a533-50b0-e053-d805fe0adaee
|
40
|
|
Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives, file e177fbc7-9d28-50b0-e053-d805fe0adaee
|
36
|
|
PD-L1 ≥ 50% lung cancer refractory to PD-1 inhibition: The role of salvage chemo-immunotherapy combination, file e177fbc7-a6a3-50b0-e053-d805fe0adaee
|
36
|
|
Fighting tertiary mutations in EGFR-driven lung-cancers: Current advances and future perspectives in medicinal chemistry, file e177fbc7-9d62-50b0-e053-d805fe0adaee
|
33
|
|
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer, file e177fbc6-c828-50b0-e053-d805fe0adaee
|
32
|
|
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells., file e177fbc5-d274-50b0-e053-d805fe0adaee
|
31
|
|
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors, file e177fbc7-9e55-50b0-e053-d805fe0adaee
|
29
|
|
Hype or hope – Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?, file e177fbc7-9fb9-50b0-e053-d805fe0adaee
|
27
|
|
Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial, file e177fbc7-a225-50b0-e053-d805fe0adaee
|
27
|
|
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer, file e177fbc4-374a-50b0-e053-d805fe0adaee
|
26
|
|
Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung cancer?, file e177fbc7-a3b3-50b0-e053-d805fe0adaee
|
25
|
|
Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: A systematic review and meta-analysis, file e177fbc7-a766-50b0-e053-d805fe0adaee
|
25
|
|
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines, file e177fbc5-e007-50b0-e053-d805fe0adaee
|
22
|
|
Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study, file e177fbc7-9dea-50b0-e053-d805fe0adaee
|
22
|
|
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients, file e177fbc7-a7e6-50b0-e053-d805fe0adaee
|
22
|
|
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC, file e177fbc6-8be1-50b0-e053-d805fe0adaee
|
21
|
|
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines, file e177fbc4-3e0a-50b0-e053-d805fe0adaee
|
20
|
|
Epidermal Growth Factor Receptor Intron-1 Polymorphism Predicts Gefitinib Outcome in Advanced Non-small Cell Lung Cancer, file e177fbc4-1a32-50b0-e053-d805fe0adaee
|
18
|
|
Dynamic evaluation of circulating mirna profile in egfr‐ mutated nsclc patients treated with egfr‐tkis, file e177fbc7-9f51-50b0-e053-d805fe0adaee
|
18
|
|
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy, file e177fbc7-a094-50b0-e053-d805fe0adaee
|
18
|
|
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study, file e177fbc7-a397-50b0-e053-d805fe0adaee
|
17
|
|
A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients?, file e177fbc7-a8db-50b0-e053-d805fe0adaee
|
17
|
|
Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial, file e177fbc7-a2cd-50b0-e053-d805fe0adaee
|
16
|
|
Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib, file e177fbc7-a512-50b0-e053-d805fe0adaee
|
16
|
|
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors, file e177fbc7-a7af-50b0-e053-d805fe0adaee
|
16
|
|
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines, file e177fbc5-2589-50b0-e053-d805fe0adaee
|
15
|
|
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines., file e177fbc6-8938-50b0-e053-d805fe0adaee
|
15
|
|
Cystic brain metastases and RET fusion in lung cancer, file e177fbc7-a54d-50b0-e053-d805fe0adaee
|
15
|
|
Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL), file e177fbc7-a6fa-50b0-e053-d805fe0adaee
|
15
|
|
Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy, file e177fbc7-a7c6-50b0-e053-d805fe0adaee
|
15
|
|
INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A multicenter prospective observational study (INVIDIa-2), file e177fbc7-a8d6-50b0-e053-d805fe0adaee
|
15
|
|
First-line immunotherapy in non-small cell lung cancer patients with poor performance status: A systematic review and meta-analysis, file e177fbc7-a9c4-50b0-e053-d805fe0adaee
|
15
|
|
Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review, file e177fbc7-2761-50b0-e053-d805fe0adaee
|
14
|
|
Emergence of a HER2-amplified clone during disease progression in an ALK-rearranged NSCLC patient treated with ALK-inhibitors: A case report, file e177fbc7-a9e3-50b0-e053-d805fe0adaee
|
14
|
|
Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy, file e177fbc7-66fd-50b0-e053-d805fe0adaee
|
13
|
|
Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary?, file e177fbc8-0437-50b0-e053-d805fe0adaee
|
13
|
|
MicroRNA Expression in Malignant Pleural Mesothelioma and Asbestosis: A Pilot Study, file e177fbc5-9912-50b0-e053-d805fe0adaee
|
12
|
|
L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC, file e177fbc7-4f23-50b0-e053-d805fe0adaee
|
12
|
|
Mutational profile of malignant pleural mesothelioma (MPM) in the phase II RAMES study, file e177fbc7-a63b-50b0-e053-d805fe0adaee
|
12
|
|
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion, file e177fbc7-5975-50b0-e053-d805fe0adaee
|
11
|
|
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The practice study, file e177fbc7-a130-50b0-e053-d805fe0adaee
|
11
|
|
Bilateral Severe Corneal Ulcer in a Patient with Lung Adenocarcinoma Treated with Gefitinib, file e177fbc7-a358-50b0-e053-d805fe0adaee
|
11
|
|
Systemic thromboembolism from a misdiagnosed non-bacterial thrombotic endocarditis in a patient with lung cancer: A case report, file e177fbc7-a7c1-50b0-e053-d805fe0adaee
|
10
|
|
Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial), file e177fbc7-a9dc-50b0-e053-d805fe0adaee
|
10
|
|
La fototerapia mirata bath-puva come trattamento di alcune reazioni cutanee avverse causte da farmaci inibitori delle tirosina-Kinasi (TKI), file e177fbc4-2e00-50b0-e053-d805fe0adaee
|
9
|
|
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation, file e177fbc7-5aef-50b0-e053-d805fe0adaee
|
9
|
|
Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial, file e177fbc7-a01a-50b0-e053-d805fe0adaee
|
9
|
|
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes, file e177fbc7-a19b-50b0-e053-d805fe0adaee
|
9
|
|
A phase 1 study of mTORC1/2 inhibitor BI 860585 as a single agent or with exemestane or paclitaxel in patients with advanced solid tumors, file e177fbc7-a3e9-50b0-e053-d805fe0adaee
|
9
|
|
Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy, file e177fbc7-a416-50b0-e053-d805fe0adaee
|
9
|
|
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer, file e177fbc7-9e00-50b0-e053-d805fe0adaee
|
8
|
|
SMO mutations confer poor prognosis in malignant pleural mesothelioma, file e177fbc7-9e15-50b0-e053-d805fe0adaee
|
8
|
|
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study, file e177fbc7-a39f-50b0-e053-d805fe0adaee
|
8
|
|
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: A multicenter study with external validation, file e177fbc7-a632-50b0-e053-d805fe0adaee
|
8
|
|
Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG, file e177fbc7-a7ad-50b0-e053-d805fe0adaee
|
8
|
|
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study, file e177fbc7-a802-50b0-e053-d805fe0adaee
|
8
|
|
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status, file e177fbc8-04cf-50b0-e053-d805fe0adaee
|
8
|
|
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib, file e177fbc4-3d29-50b0-e053-d805fe0adaee
|
7
|
|
Letter comments on: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression, file e177fbc7-9e03-50b0-e053-d805fe0adaee
|
7
|
|
Relationship Between the Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) and Lung Adenocarcinoma Patterns: New Possible Insights, file 9cbeafa1-8654-423e-ab82-f309ae8ac50e
|
6
|
|
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study, file e177fbc7-9f98-50b0-e053-d805fe0adaee
|
6
|
|
Treatment patterns among patients with malignant pleural mesothelioma: An Italian, population-based nationwide study, file e177fbc7-a1e7-50b0-e053-d805fe0adaee
|
6
|
|
Cell-free DNA from cerebrospinal fluid can be used to detect the EGFR mutation status of lung adenocarcinoma patients with central nervous system metastasis, file e177fbc7-a223-50b0-e053-d805fe0adaee
|
6
|
|
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy, file e177fbc7-a716-50b0-e053-d805fe0adaee
|
6
|
|
Transient asymptomatic pulmonary opacities and interstitial lung disease in EGFR-mutated non-small cell lung cancer treated with osimertinib, file e177fbc7-a8dd-50b0-e053-d805fe0adaee
|
6
|
|
The role of the microbiome in cancer and therapy efficacy: Focus on lung cancer, file e177fbc7-a994-50b0-e053-d805fe0adaee
|
6
|
|
Exploring the role of respiratory microbiome in lung cancer: A systematic review, file e177fbc7-aae6-50b0-e053-d805fe0adaee
|
6
|
|
Fighting tertiary mutations in EGFR-driven lung-cancers: Current advances and future perspectives in medicinal chemistry, file e177fbc7-2765-50b0-e053-d805fe0adaee
|
5
|
|
Adding PD-1/PD-L1 inhibitors to chemotherapy for the first-line treatment of extensive stage small cell lung cancer (Sclc): A meta-analysis of randomized trials, file e177fbc7-a7bf-50b0-e053-d805fe0adaee
|
5
|
|
FGFR as potential target in the treatment of squamous non small cell lung cancer, file e177fbc7-6701-50b0-e053-d805fe0adaee
|
4
|
|
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%, file e177fbc7-a3bb-50b0-e053-d805fe0adaee
|
4
|
|
Optimizing PD-L1 evaluation on cytological samples from advanced non-small-cell lung cancer, file e177fbc7-b35f-50b0-e053-d805fe0adaee
|
4
|
|
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status, file e177fbc8-04ce-50b0-e053-d805fe0adaee
|
4
|
|
FGFR as potential target in the treatment of squamous non small cell lung cancer, file e177fbc4-8f67-50b0-e053-d805fe0adaee
|
3
|
|
ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients, file e177fbc5-1804-50b0-e053-d805fe0adaee
|
3
|
|
IASLC and WHO 2004 Grading System as Prognostic Factors in 492 Cases of Pulmonary Adenocarcinoma, file e177fbc5-2cfb-50b0-e053-d805fe0adaee
|
3
|
|
The role of miRNA-221 and miRNA-126 in patients with benign metastasizing leiomyoma of the lung: an overview with new interesting scenarios, file e177fbc7-999b-50b0-e053-d805fe0adaee
|
3
|
|
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation, file e177fbc7-9f9a-50b0-e053-d805fe0adaee
|
3
|
|
L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib, file e177fbc7-a8b4-50b0-e053-d805fe0adaee
|
3
|
|
Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’: [ESMO Open Volume 6, Issue 2, April 2021, 100078] (ESMO Open (2021) 6(2), (S205970292100034X), (10.1016/j.esmoop.2021.100078)), file e177fbc7-ac03-50b0-e053-d805fe0adaee
|
3
|
|
Integrated CT imaging and tissue immune features disclose a radio-immune signature with high prognostic impact on surgically resected NSCLC, file e177fbc7-b35d-50b0-e053-d805fe0adaee
|
3
|
|
Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer, file d9ef1511-b26b-4ec8-a599-23a03fa4141c
|
2
|
|
Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines, file e177fbc4-1f39-50b0-e053-d805fe0adaee
|
2
|
|
Expression levels of some antioxidant and epidermal growth factor genes on patients with early stage non small cell lung cancer, file e177fbc4-2513-50b0-e053-d805fe0adaee
|
2
|
|
Grading the neuroendocrine tumors of the lung: an evidence-based proposal., file e177fbc4-3fd7-50b0-e053-d805fe0adaee
|
2
|
|
Curved Needles in CT-Guided Fine Needle Biopsies of Abdominal and Retroperitoneal Small Lesions, file e177fbc4-b513-50b0-e053-d805fe0adaee
|
2
|
|
Semiautomatic analysis on computed tomography in locally advanced or metastatic non-small cell lung cancer: Reproducibility and Prognostic Significance of Unidimensional and 3-dimensional Measurements., file e177fbc4-ee7e-50b0-e053-d805fe0adaee
|
2
|
|
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN, file e177fbc5-953c-50b0-e053-d805fe0adaee
|
2
|
|
Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC, file e177fbc6-281f-50b0-e053-d805fe0adaee
|
2
|
|
The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors, file e177fbc6-d564-50b0-e053-d805fe0adaee
|
2
|
|
Wide and cystic brain metastases reveal RET-rearranged non–small-cell lung cancers, file e177fbc7-1c7e-50b0-e053-d805fe0adaee
|
2
|
|
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation, file e177fbc7-56f9-50b0-e053-d805fe0adaee
|
2
|
|
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine, file e177fbc7-9c8b-50b0-e053-d805fe0adaee
|
2
|
| Totale |
1.481 |